The U.S. Food and Drug Administration approved Heron Therapeutics Inc.’s Zynrelef (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty.
The U.S. Food and Drug Administration approved Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery.
The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
The U.S. FDA approved Bausch + Lomb’s Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for treating postoperative inflammation and pain following ocular surgery.
International non-profit organization Lifebox, in partnership with healthcare advertising agency precisioneffect, will launch the “Deadliest Conditions” campaign as the American College of Surgeons holds the 2018 Clinical Congress in Boston starting October 21st.
Bausch + Lomb announced the U.S. FDA accepted the New Drug Application for the company’s sub-micron loteprednol etabonate ophthalmic gel 0.38% with a PDUFA date of Feb. 25, 2019.
Lumicell Inc. announced the presentation of clinical data from its ongoing Phase 2 breast cancer trial with the LUM System, which integrates the immuno- and cancer-targeted optical agent LUM015, the Lumicell handheld imaging device and decision software to detect cancer cells in real-time during surgery.
Lumicell Inc. provided an update on the company’s development strategy for its LUM system pipeline including plans to initiate its pivotal trial in breast cancer as well as expansion of its clinical studies in four other solid tumor cancers.
